Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) announced on February 27 that it has hired Eric Chapdelaine, Senior Director of Pharmaceutical Sciences and Manufacturing, and Kalyn Dabbs, Senior Manager of Communications and Marketing. The move to grow the company’s senior team is in accordance with Genprex’s preparation to expand its operations and focus on corporate communications in 2019. Chapdelaine will be tasked with overseeing analytical development, chemistry, manufacturing and controls, technical operations and supply chain management for the company. Dabbs will oversee the development and implementation of internal and external communication and marketing plans as well as managing the company’s digital strategy. “Having Eric and Kalyn join the Genprex team will bring value to the company and enhance our growth and communication efforts,” Genprex CEO and Chairman Rodney Varner stated in the news release. “Eric’s experience at both biotech companies and contract development and manufacturing organizations will be invaluable in managing and coordinating manufacturing partners and scale-up activities as we expand our research and development efforts and clinical trials of our lead product candidate, Oncoprex(TM), at the University of Texas MD Anderson Cancer Center and potentially other clinical sites.”
To view the full press release, visit http://nnw.fm/i1ryV
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. For more information, visit the company’s website at www.Genprex.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive instant SMS alerts, text STOCKS to 77948
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com